[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 8, Number 4 (7-2017) ::
Caspian J Intern Med 2017, 8(4): 239-249 Back to browse issues page
Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
Gholamreza Badfar, Akram Mansouri, Masoumeh Shohani, Hamid Karimi, Zahra Khalighi, Shoboo Rahmati, Ali Delpisheh, Yousef Veisani, Ali Soleymani, Milad Azami *
Student Research Committee, Dezful University of Medical Sciences , Dezful, Iran , milad98azami@gmail.com
Abstract:   (423 Views)

Background: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine.
Methods: This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SID, Scopus, PubMed, Science Direct, Web of Science and Google Scholar without time limit until May 2017. Cochran's Q test and I2 index were used to assess the heterogeneity of the studies. The data were analyzed using Comprehensive Meta-Analysis software version 2 and p<0.05 was considered significant.
Results: A total of 17 articles involving 1,835 Iranian thalassemia major patients treated with deferoxamine were included in the meta-analysis. The overall prevalence of hearing loss was estimated 27.3% (95% confidence intervals (CI): 19-37.6). The prevalence of sensorineural, conductive and mixed hearing loss was estimated 10.6% (95% CI: 5.7-18.8), 14.6% (95% CI: 10.5-20.6) and 9.1% (95% CI: 5.6-14.6), respectively. No significant differences were noted regarding the relationship hearing loss and mean serum ferritin (P=0.29) and average daily deferoxamine (P=0.30). Meta-regression model showed an increased significance in the prevalence of hearing loss based on the year of studies (p<0.0001).
Conclusions: There is a high prevalence of hearing loss in Iranian thalassemia major patients treated with deferoxamine. Therefore, periodic hearing assessments and regular check-ups after the initiation of chelation therapy are necessary.

Keywords: Hearing Loss, Thalassemia Major, Deferoxamine, Systematic Review, Meta-analysis, Iran
Full-Text [PDF 858 kb]   (31 Downloads)    
Type of Study: Review Article | Subject: Pediatrics
Received: 2016/08/2 | Accepted: 2017/07/8 | Published: 2017/07/29
Send email to the article author

Add your comments about this article
Your username or email:

Write the security code in the box >



DOI: 10.22088/cjim.8.4.239


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Badfar G, Mansouri A, Shohani M, Karimi H, Khalighi Z, Rahmati S, et al . Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis . Caspian J Intern Med. 2017; 8 (4) :239-249
URL: http://caspjim.com/article-1-828-en.html
Volume 8, Number 4 (7-2017) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.051 seconds with 812 queries by yektaweb 3461